Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 28, 2009Haemostasis

Lack of Anti-Factor Xa Activity in Umbilical Cord Vein Samples after Subcutaneous Administration of Heparin or Low Molecular Mass Heparin in Pregnant Women

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does subcutaneous administration of unfractionated heparin or low molecular mass heparin cross the placenta in pregnant women undergoing delivery?

Population

60 pregnant women undergoing delivery at term

Comparison

Subcutaneous administration of 5,000 IU… vs Placebo

Design

RCT, randomized

Follow-up

about 2 hours (at delivery)

Authors

JHJob HarenbergHeidelberg UniversityDSDaniela SchneiderForschungszentrum JülichLHL. HeilmannUniversity of Freiburg

Discussion

Loading...

Member takes

Overview

Supports safe use of unfractionated and low-molecular-mass heparin for thromboembolism prophylaxis in pregnancy; confirms no placental transfer in this RCT.

Structured PICO

Does subcutaneous administration of unfractionated heparin or low molecular mass heparin cross the placenta in pregnant women undergoing delivery?

P
Population
60 pregnant women undergoing delivery at term
I
Intervention
Subcutaneous administration of 5,000 IU unfractionated (UF) heparin or 1,500 activated partial thromboplastin time units low molecular mass (LMM) heparin injected about 2 hours prior to delivery
C
Comparator
Placebo
O
Outcome
Anti-factor Xa activities in maternal plasma and umbilical cord vein plasma of the newbornsurrogate

Neither unfractionated nor low molecular mass heparin cross the placenta in relevant inhibitory activity towards factor Xa, supporting their safe use for thromboembolism prophylaxis during pregnancy.

Cite This Study

Harenberg et al. (2009) studied this question.

synapsesocial.com/papers/6a707cdbf44fa9f079de2331https://doi.org/10.1159/000216894
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of Low Molecular Weight Heparin in Pregnancy1992 · 181 citations
  2. 2Low molecular mass heparin (LMMH) for management of thromboembolic disease in pregnancy2005 · 1 citations
  3. 3During pregnancy, anticoagulant effect of low molecular weight heparin can be determined with both thrombelastography and anti-factor Xa activity, or not?2026
  4. 4Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review1999 · 554 citations
  5. 5Thromboembolic prophylaxis with low molecular weight heparin during pregnancy1994 · 46 citations